Iteos Therapeutics Inc (ITOS) — Cash Flow-to-Debt Ratio
Iteos Therapeutics Inc (ITOS) has a Cash Flow-to-Debt Ratio of -0.33x as of June 2025, meaning its operating cash flow of $-42.45 Million could theoretically repay 0% of its total liabilities ($129.28 Million) in one year. See cash generation quality of Iteos Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Iteos Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Iteos Therapeutics Inc across 7 annual periods. Also explore net asset momentum of Iteos Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Iteos Therapeutics Inc (2018–2024)
Year-by-year debt coverage analysis for Iteos Therapeutics Inc. For market capitalisation and broader financial context, see ITOS company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.02x | $-98.18 Million | $96.68 Million | ▲ +9.6% |
| 2023 | -1.12x | $-103.76 Million | $92.36 Million | ▲ +7.4% |
| 2022 | -1.21x | $-111.19 Million | $91.66 Million | ▼ -178.5% |
| 2021 | 1.55x | $513.14 Million | $331.89 Million | ▲ +231.2% |
| 2020 | -1.18x | $-25.18 Million | $21.36 Million | ▲ +23.2% |
| 2019 | -1.54x | $-23.14 Million | $15.07 Million | ▲ +0.8% |
| 2018 | -1.55x | $-19.10 Million | $12.34 Million | — |